Skip to main content

Table 1 Baseline characteristics after matching for JIA and ADHD groups

From: Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study

Characteristic

<  18 years

≥ 18 years

MarketScan

PharMetrics

MarketScan

PharMetrics

JIA (N = 8633)

ADHD (N = 38,967)

JIA (N = 9155)

ADHD (N = 41,264)

JIA (N = 5789)

ADHD (N = 27,288)

JIA (N = 5638)

ADHD (N = 27,106)

Female

6173 (71.5)

26,933 (69.1)

6587 (71.9)

28,694 (69.5)

4506 (77.8)

21,096 (77.3)

4315 (76.5)

20,590 (76.0)

Age, mean (SD)

10.6 (4.5)

11.1 (3.9)

10.5 (4.5)

11.0 (3.9)

37.0 (16.5)

36.2 (15.4)

34.6 (14.7)

34.4 (14.3)

Medications

 bDMARD

1287 (14.9)

9 (<  0.1)

1485 (16.2)

9 (<  0.1)

1593 (27.5)

121 (0.4)

1614 (28.6)

129 (0.5)

 Non-bDMARD

2512 (29.1)

529 (1.4)

3127 (34.2)

534 (1.3)

2143 (37.0)

870 (3.2)

2266 (40.2)

845 (3.1)

 Corticosteroidsa

2984 (34.6)

7500 (19.2)

3367 (36.8)

4696 (11.4)

2681 (46.3)

7845 (28.7)

2712 (48.1)

8496 (31.3)

 NSAIDs

4090 (47.4)

3037 (7.8)

4812 (52.6)

9868 (23.9)

2528 (43.7)

7391 (27.1)

2634 (46.7)

8101 (29.9)

Comorbidities

 Multiple sclerosis

1 (<  0.1)

11 (<  0.1)

1 (<  0.1)

8 (<  0.1)

20 (0.3)

87 (0.3)

19 (0.3)

65 (0.2)

 Asthma

777 (9.0)

4130 (10.6)

887 (9.7)

5410 (13.1)

472 (8.2)

2279 (8.4)

486 (8.6)

2565 (9.5)

 Anxiety

295 (3.4)

6123 (15.7)

317 (3.5)

7665 (18.6)

555 (9.6)

8098 (29.7)

549 (9.7)

9185 (33.9)

 Depression

208 (2.4)

4478 (11.5)

214 (2.3)

5293 (12.8)

653 (11.3)

9469 (34.7)

622 (11.0)

9868 (36.4)

 Diabetes mellitus

92 (1.1)

240 (0.6)

84 (0.9)

259 (0.6)

440 (7.6)

1408 (5.2)

371 (6.6)

1146 (4.2)

 Anemia

498 (5.8)

540 (1.4)

479 (5.2)

741 (1.8)

948 (16.4)

1762 (6.5)

655 (11.6)

1674 (6.2)

 Hypertension

2 (<  0.1)

11 (<  0.1)

6 (0.1)

9 (<  0.1)

103 (1.8)

268 (1.0)

103 (1.8)

319 (1.2)

 Hyperlipidemia

174 (2.0)

987 (2.5)

202 (2.2)

1388 (3.4)

1162 (20.1)

5355 (19.6)

1023 (18.1)

5264 (19.4)

 Malignancy

56 (0.6)

128 (0.3)

49 (0.5)

136 (0.3)

278 (4.8)

856 (3.1)

162 (2.9)

702 (2.6)

CCI score, mean (SD) [40]

2.4 (0.6)

2.1 (0.4)

2.4 (0.6)

2.1 (0.5)

2.9 (1.0)

2.3 (0.7)

2.8 (0.9)

2.2 (0.7)

Autoimmune diseasesb

 0

4988 (57.8)

37,675 (96.7)

5194 (56.7)

39,680 (96.2)

1973 (34.1)

24,792 (90.9)

2029 (36.0)

24,739 (91.3)

 1

2830 (32.8)

1220 (3.1)

3075 (33.6)

1510 (3.7)

2749 (47.5)

2160 (7.9)

2641 (46.8)

2052 (7.6)

 2

659 (7.6)

63 (0.2)

745 (8.1)

67 (0.2)

796 (13.8)

283 (1.0)

722 (12.8)

261 (1.0)

 3

127 (1.5)

8 (<  0.1)

121 (1.3)

7 (<  0.1)

190 (3.3)

42 (0.2)

190 (3.4)

42 (0.2)

  > 3

29 (0.3)

1 (<  0.1)

20 (0.2)

0 (0.0)

81 (1.4)

11 (<  0.1)

56 (1.0)

12 (<  0.1)

Healthcare encountersc

 0–10

4927 (57.1)

22,969 (58.9)

3205 (35.0)

15,400 (37.3)

2713 (46.9)

13,157 (48.2)

1656 (29.4)

8139 (30.0)

 11–20

2353 (27.3)

9995 (25.6)

3352 (36.6)

14,630 (35.5)

1567 (27.1)

7352 (26.9)

1741 (30.9)

8371 (30.9)

 21–30

739 (8.6)

3235 (8.3)

1393 (15.2)

5930 (14.4)

730 (12.6)

3346 (12.3)

1008 (17.9)

4829 (17.8)

 31–40

294 (3.4)

1318 (3.4)

604 (6.6)

2607 (6.3)

371 (6.4)

1677 (6.1)

561 (10.0)

2655 (9.8)

 41–50

153 (1.8)

701 (1.8)

262 (2.9)

1150 (2.8)

183 (3.2)

821 (3.0)

273 (4.8)

1295 (4.8)

  > 50

167 (1.9)

749 (1.9)

339 (3.7)

1547 (3.7)

225 (3.9)

935 (3.4)

399 (7.1)

1817 (6.7)

  1. Data are shown as n (%) unless otherwise specified
  2. aBy any route of administration
  3. bIncludes all autoimmune diseases outlined in Supplementary Table 1, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, dermatomyositis, systemic lupus erythematosus, and sarcoidosis
  4. cIn 1 year
  5. ADHD attention deficit hyperactivity disorder, bDMARD biologic disease-modifying antirheumatic drug, CCI Charlson Comorbidity Index [40], JIA juvenile idiopathic arthritis, MarketScan Truven Health MarketScan® Commercial Database, NSAID nonsteroidal anti-inflammatory drug, PharMetrics IMS PharMetrics database, SD standard deviation